



Коронавирус

Статистические аспекты

Распространенность в мире

Всего случаев
134 678

Зараженных
60 563

Завершенных
74 115

Стабильные
54 569


В критической
стадии
5 994

Выздоровевших
69 142


Умерших
4 973

Смертность в мире

Всего Случаев Заражения



Смертность



Распространенность по странам

Поз.	Страна	Заражено	Выздоровело	Умерло
1	Китай 	14 753	62 874	3 170
2	Италия 	15 113	1 258	1 016
3	Иран 	10 075	3 276	429
4	Ю.Корея 	7 979	510	67
5	Испания 	3 146	189	86
6	Франция 	2 876	12	61
7	Германия 	2 745	25	6
..				
49	Россия 	34	3	0



Коронавирус – взгляд через патентные очки

Методология поиска и анализа

Поисковый запрос:

(Coronavirus OR covid-19) AND (drug OR treatment OR therapy OR vaccine) AND IPC(A61)

Аналитическая система: LexisNexis PatentSight

The screenshot displays the LexisNexis PatentSight search interface. At the top, the 'PATENTSIGHT' logo is visible. Below it, a navigation bar includes icons for 'Owner', 'IPC', 'Tag', 'EP...', 'F', 'Authority', 'Time', 'Indicator', and 'More'. The main search area is titled 'Search' and shows a multi-step search process:

- Step 1:** Searching active patent families. Hide options. Includes toggle switches for 'Incl. inactive' and 'Incl. Chinese utility models'. The search criteria are 'English text' with checkboxes for 'Title', 'Abstract', 'Claims', and 'Description'. The search term is 'coronavirus OR covid-19', resulting in 10 749 documents.
- Step 2:** The search is refined with 'AND' and the criteria 'English text' with 'Title', 'Abstract', 'Claims', and 'Description' checked. The search term is 'drug OR treatment OR therapy OR cure OR vaccine', resulting in 8 916 547 documents.
- Step 3:** The search is further refined with 'AND' and 'IPC (smart)' selected, with 'A61' chosen from the dropdown menu.

На март 2020 года мы видим 855 патентных семейств

coronavirus covid-19 drug treatment therapy cure vaccine Select Sorted by: First filing ↓

- Porcine delta coronavirus and application thereof** 2019
 The vaccine prepared by the separation strain can induce the (Porcine delta coronavirus) piglet to. generate a high level of neutralizing ant...
 <unknown> CN110747175.A
- A composition for preventing or treating MERS-CoV virus comprising HBD2 (human beta-defensin 2) or an fusion protein comprisin...** 2019
 The present invention HBD2(human beta-defensin 2) relates to a composition for preventing or treating a Merck coronavirus comprising a...
 Chonbuk National Univ. KR20190134578.A
- Use of RNase L inhibitors of HIV** 2019
 The invention discloses application of, RNase L a specific compound of a specific compound in RNase L preparation, of an anti-tumor, po...
 <unknown> CN110638846.A
- Pharmaceutical composition for treating canine coronavirus disease and preparation method and application of pharmaceutical co...** 2019
 The invention discloses a traditional Chinese medicine composition for treating a canine coronavirus disease and a preparation method a...
 JIANGSU AGRICULTURAL ANIMAL HUSBANDRY VOCATIONAL COLLEGE CN110420274.A
- Pyrrrolotriazinoid-based compound as, well as application thereof** 2019
 The invention relates to a pyrrrolotriazinoid compound as well as, a composition and application thereof, and the, pyrrrolotriazine-based co...
 <unknown> CN110724174.A
- Broad-spectrum antiviral drug or composition** 2019
 The invention provides a broad-spectrum antiviral drug or composition. The drug or composition is prepared from the active components ...
 China Agricultural University CN110403941.A
- System, method and application for saving swine enteric alphacoronavirus** 2019
 The invention discloses a system, a method and application for saving swine enteric alphacoronavirus. The system comprises a recomb...
 Zhejiang University CN110468155.A
- Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immuno...** 2019
 Disclosed herein are methods for treating patients that may develop or already have pre-existing gene therapy neutralizing antibodies by ...
 GENETHON SA, Inserm, Paris Descartes University, Paris Diderot University, Roche, Sorbonne University WO2020016318.A1
- Prevention and treatment of viral infections** 2019
 The present disclosure targets the Zika virus and other disease-causing microbes including viruses, bacteria, fungi, and parasites. It does...
 <unknown> BARANOWITZ STEVEN IIS2019380995 A1

Family of CN110747175.A


Porcine delta coronavirus and application thereof

The vaccine prepared by the separation strain can induce the (Porcine delta coronavirus) piglet to. generate a high level of neutralizing antibodies, and can be used for inducing the piglet to generate PDC - SX19, high-level neutralizing CGMCC No.18332. antibodies, and the vaccine can be used for detecting, the porcine delta coronavirus. in serum at the same time; ELISA. (Source: CN110747175.A , machine translation)

<unknown>

First filing in family 09.12.2019

First publication in family 04.02.2020



Inventor <Unknown>

Applicant <Unknown>

Family members (1)


Document #	Title	Publication date
© CN110747175.A	Porcine delta coronavirus and application thereof	04.02.2020 Pending E

Indicators	Table...	Legal status today	Legal events...
Competitive Impact™ (CI)	0,4 ↗	In force	-
Market Coverage™ (MC)	0,4 ↗	Pending	CN
Technology Relevance™ (TR)	1,0 ↘	Inactive	-

Prior art (0)

Subsequent art (0)

Больше всего патентов имеет Boehringer Ingelheim, а наиболее сильные патенты Shanghai Junshi Biosciences



Owner (bubbles) shows items 1-10 of 583, sorted by Patent Asset Index™ desc as at 05.03.2020.

2018

Analysis based on 855 patent families active at 05.03.2020....(more)

Патенты Dr. Reddy's Laboratories

coronavirus covid-19 drug treatm Select Sorted by: CI ↓

- Cyclic peptidomimetic compounds as immunomodulators** 2014
 The present invention relates to cyclic peptidomimetic comp...
 Dr. Reddy's Laboratories EP3041468.A1
- Dual inhibitors of tim-3 and pd-1 pathways** 2018
 The present disclosure relates to 3-substituted 1,2,4-oxadiaz...
 Dr. Reddy's Laboratories WO2019087087.A1
- Conjoint therapies for immunomodulation** 2018
 The present disclosure relates to methods comprising admin...
 Curis, Dr. Reddy's Laboratories WO2019087092.A1
- Method of modulating tigit and pd-1 signalling pathways...** 2019
 The present invention relates to method of modulating TIGIT ...
 Dr. Reddy's Laboratories WO2019175799.A2
- Dual inhibitors of vista and pd-1 pathways** 2017
 The present disclosure relates to 3-substituted 1,2,4-oxadiaz...
 Dr. Reddy's Laboratories EP3529235.A1

Family of EP3041468.A1 et al.

Cyclic peptidomimetic compounds as immunomodulators

The present invention relates to cyclic peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentialization comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them. (Source: EP3041468.A1, equivalent)

Dr. Reddy's Laborat...

First filing in family 05.09.2014
 First publication in family 12.03.2015

Inventors Muralidhara Ramachandra, Nair Sasikumar Pottayil Govindan, Naremaddepalli Seeth, ...
Applicants Aurigene Discovery Tech Ltd, Aurigene Discovery Tech Limited, Aurigene Discovery, ...

Family members (86)

Document #	Title	Publication date	Legal status
EP3041468.A1	Cyclic peptidomimetic compounds as immunomodulators	13.07.2016	Inactive
AU2014316682.A1	1,2,4-oxadiazole derivatives as immunomodulators	28.04.2016	In force
AU2014316682.B2	1,2,4-oxadiazole derivatives as immunomodulators	22.11.2018	In force
AU2014316686.A1	Cyclic peptidomimetic compounds as immunomodulators	28.04.2016	In force
AU2014316686.B2	Cyclic peptidomimetic compounds as immunomodulators	22.11.2018	In force

Indicators

Indicator	Value	Trend
Competitive Impact™ (CI)	81,9	↑
Market Coverage™ (MC)	3,3	↑
Technology Relevance™ (TR)	24,9	↑

Legal status today

In force: AL, AT, AU, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, ...
 Pending: BR, CA, CU, EA, IL, KR, PH, SG
 Inactive: EP, MT, WG

Prior art (39)

Entity	Filed	PAI
Roche	1992-2009	334,9
Ono Pharmaceutical	2006	329,9

Subsequent art (62)

Entity	Filed	PAI
Bristol-Myers Squibb	2014-2017	280,6
Dr. Reddy's Laboratories	2014-2019	173,7

Патенты Boehringer Ingelheim

coronavirus covid-19 drug treatm Select Sorted by: CI ↓

- Vaccine formulations comprising an oil-in-water emulsion** 2004
 The present invention provides for a novel oil-in-water (O/W) ...
[Boehringer Ingelheim](#) EP1651265.A2
- Multivalent pcv2 immunogenic compositions and metho...** 2006
 An improved method for recovering the protein expressed by ...
[Boehringer Ingelheim](#) EP1968630.A2
- Stabilizers for freeze-dried vaccines** 2006
 The present invention relates generally to the fields of immu...
[Boehringer Ingelheim](#) EP1954308.A2
- Novel immunogenic formulations comprising linear or br...** 2017
 The present invention provides for novel immunological and ...
[Boehringer Ingelheim, Sanofi](#) EP3471760.A1
- Immunogenic compositions comprising lawsonia intrace...** 2006
 The present invention provides combination vaccines that co...
[Boehringer Ingelheim](#) EP1865984.A1
- Recombinant hvt vectors expressing antigens of avian p...** 2012
 The present invention provides recombinant herpesvirus of t...
[Boehringer Ingelheim](#) EP2785373.A1
- Use of meloxicam for the treatment of respiratory disea...** 2004
 The invention relates to the use of meloxicam or a pharmace...
[Boehringer Ingelheim](#) EP1720554.A1
- Vaccines comprising attenuated mycoplasma bovis strai...** 2010
 The present invention relates to new attenuated M. bovis bac...
[Boehringer Ingelheim](#) EP2421556.A1
- Recombinant hvt vectors expressing multiple antigens o...** 2017
 The present invention provides recombinant herpesvirus of t...
[Boehringer Ingelheim](#) EP3554536.A1
- Porcine coronavirus vaccines** 2018

Family of EP1651265.A2 et al.

- Vaccine formulations comprising an oil-in-water emulsion**
 The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified or weakly purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group comprising an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof. (Source: EP1651265.A2, equivalent)

Inventors Catherine Charreyre, Catherine Parisot Alexis Guy A, Des Gouilles-Blechet Stephanie, ...

Applicants Andre Parisot Alexis Guy, Catherine Charreyre, Desgouilles Blechet Stephanie, Desgo, ...

Boehringer Ingelheim

First filing in family 26.07.2004
 First publication in family 03.02.2005

weight of the hydr

ght of the amphiphil

Family members (37)

Document #	Title	Publication date	Status
EP1651265.A2	Vaccine formulations comprising an oil-in-water emulsion	03.05.2006	Inactive
AT392905.T	Vakzin formulations with an oil in water an emulsion	15.05.2008	In force
AU2004259034.A1	Vaccine formulations comprising an oil-in-water emulsion	03.02.2005	In force
AU2004259034.B2	Vaccine formulations comprising an oil-in-water emulsion	07.05.2009	In force
AU2004259034.C1	Vaccine formulations comprising an oil-in-water emulsion	16.12.2010	In force

Indicators Table...

Competitive Impact™ (CI)	32,3	
Market Coverage™ (MC)	3,0	
Technology Relevance™ (TR)	10,9	

Legal status today Legal events...

In force	AT, AU, BE, BG, BR, CA, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, ...
Pending	-
Inactive	EP, HK, HR, JP, MX, PL, PT, UA, WO

Prior art (13) Expand all

	Filed	PAI
Boehringer Ingelheim	1998-2000	10,7
Novartis	2000	1,1

Subsequent art (95) Expand all

	Filed	PAI
Boehringer Ingelheim	2005-2017	256,0
Sanofi	2005-2017	86,7

Патенты Shanghai Junshi Biosciences

coronavirus covid-19 drug treatm Select Sorted by: CI ↓

- **Anti-pd-1 antibody and use thereof** 2013
This invention provides antibodies or functional fragments th...
JUNMENG BIOSCIENCES, SHANGHAI JUNSHI BIOSC... EP3026062.A1

Family of EP3026062.A1 et al.

● Anti-pd-1 antibody and use thereof

This invention provides antibodies or functional fragments thereof that bind to PD-1 with high affinity. The invention provides nucleic acid molecules encoding the antibodies or the fragments thereof according to the present invention, expression vectors and host cells for expressing the antibodies or the functional fragments thereof according to the present invention, as well as methods for producing the antibodies or the functional fragments thereof according to the present invention. The present invention also provides immunoconjugates and pharmaceutical compositions comprising the antibodies or the functional fragments thereof according to the present invention. The present invention additionally provides methods for treating a plurality of diseases (comprisin...


Inventors Bo Chen, Feng Hui, Wu Hai

Applicants Junmeng Biosciences Co Ltd, Shanghai Junshi Biosciences Co Ltd, Shanghai Junshi, ...

JUNMENG BIOSC..., ...

First filing in family 26.06.2013

First publication in family 31.12.2014



Family members (13)

Document #	Title	Publication date	Status	Icons
EP3026062.A1	Anti-pd-1 antibody and use thereof	01.06.2016	Pending	🔍 📄 📑
BR112015031883.A2		14.02.2018	Pending	🔍 📄 📑
CN104250302.A	Anti-PD-1 antibody and its application	31.12.2014	In force	🔍 📄 📑
CN104250302.B	Anti-PD - 1 antibody and application thereof	14.11.2017	In force	🔍 📄 📑
EP3026062.A1	Anti-pd-1 antibody and use thereof	16.06.2017	Pending	🔍 📄 📑

Indicators

Indicator	Value	Trend
Competitive Impact™ (CI)	69,6	↗️
Market Coverage™ (MC)	2,7	↗️
Technology Relevance™ (TR)	26,2	↗️

Legal status today

In force	CN, RU, US
Pending	BR, EP, JP, PH
Inactive	WG


Prior art (14)

	Filed	PAI	Bar
Ono Pharmaceutical	2006	329,9	██████████
Bristol-Myers Squibb	2006	220,0	██████████

Subsequent art (62)

	Filed	PAI	Bar
Agenus	2016-2019	237,5	██████████
Bristol-Myers Squibb	2016-2019	107,5	██████████


Динамика патентования за последние 10 лет: у кого сколько патентов?



Owner (lines) shows items 1-10 of 584, sorted by Portfolio Size desc as at 05.03.2020.

Analysis based on 855 patent families active at 05.03.2020.


Динамика силы патентов: у кого самые сильные патенты?



Owner (lines) shows items 41-50 of 583, sorted by Technology Relevance™ desc as at 05.03.2020.

Analysis based on 855 patent families active at 05.03.2020....(more)


Какие компании развивают какие области?



Owner (x-axis) shows items 1-10 of 583, sorted by Patent Asset Index™ desc as at 05.03.2020....(more)

Analysis based on 855 patent families active at 05.03.2020....(more)

Где находятся центры НИОКР?



Geography: Authority - origin


≥ 0 ≥ 150 ≥ 300 ≥ 450

Shading: Patent Asset Index™

≥ 600 ≥ 750 ≥ 900 ≥ 1 050 ≥ 1 200 ≥ 1 350 ≥ 1 500 ≥ 1 650 ≥ 1 800 ≥ 1 950 ≥ 2 100 ≥ 2 250 ≥ 2 400 ≥ 2 550 ≥ 2 700 ≥ 2 850 ≥ 3 000



Где разработчики патентуют свои изобретения? (где они собираются их продавать?)




Изобретатели (сортировка по силе патентов)

✓	Original Inventor	Patent Asset Index™	Competitive Impact™	Technology Relevance™	Market Coverage™	Portfolio Size
1	CHEN BING	330	329,9	99,8	3,3	1
2	WANG CHANG-YU	330	329,9	99,8	3,3	1
3	HUANG HAICHUAN	330	329,9	99,8	3,3	1
4	SRINIVASAN MOKHAN	330	329,9	99,8	3,3	1
5	CHEN BIN	330	329,9	99,8	3,3	1
6	CARDARELLI JOSEP...	330	329,9	99,8	3,3	1
7	SELBI MARK DZH	330	329,9	99,8	3,3	1
8	CHEN BINGLIANG	330	329,9	99,8	3,3	1
9	SELLBY MARK J	330	329,9	99,8	3,3	1
10	JOSEPHINE M CARD...	330	329,9	99,8	3,3	1
11	CHEHN BIN	330	329,9	99,8	3,3	1
12	VAN CHANJUJ	330	329,9	99,8	3,3	1
13	VAN CHANYUJ	330	329,9	99,8	3,3	1
14	BING CHEN	330	329,9	99,8	3,3	1
15	CARDARELLI JOSEP...	330	329,9	99,8	3,3	1
16	KARDARELLI ZHOZE...	330	329,9	99,8	3,3	1
17	CARDARELLI JOSEP...	330	329,9	99,8	3,3	1
18	KORMAN ALAN DZH	330	329,9	99,8	3,3	1
19	KHUAN KHAJCHUN	330	329,9	99,8	3,3	1
20	MARK J SELBY	585	292,7	92,3	3,2	2
21	WANG CHANGYU	585	292,7	92,3	3,2	2
22	CHANGYU WANG	585	292,7	92,3	3,2	2
23	SELBY MARK J	585	292,7	92,3	3,2	2
24	ALAN J KORMAN	585	292,7	92,3	3,2	2
25	HUANG HAICHUN	585	292,7	92,3	3,2	2
26	HAICHUN HUANG	585	292,7	92,3	3,2	2
27	CHEN HAIBIN	255	255,5	84,9	3,0	1
28	HAIBIN CHEN	255	255,5	84,9	3,0	1

Изобретатели (сортировка по силе патентов)

✓ IPC	Patent Asset Index™	Portfolio Size	Competitive Impact™	Technology Relevance™	Market Coverage™
1 A61P 31: Antiinfectives, i.e. antibiotics, antiseptics, chemotherap...	3 157	626	5,0	2,3	1,5
2 A61K 39: Medicinal preparations containing antigens or antibodye...	2 559	441	5,8	2,6	1,6
3 A61P 37: Drugs for immunological or allergic disorders	2 222	222	10,0	4,1	2,0
4 A61P 35: Antineoplastic agents	2 185	196	11,1	4,6	1,9
5 A61K 31: Medicinal preparations containing organic active ingred...	1 770	372	4,8	2,3	1,6
6 A61P 43: Drugs for specific purposes, not provided for in groups	1 662	138	12,0	4,9	2,0
7 A61Kmiss: PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PU...	1 557	161	9,7	3,8	2,1
8 A61K 47: Medicinal preparations characterised by the non-active i...	1 541	133	11,6	4,6	2,0
9 A61K 38: Medicinal preparations containing peptides (peptides c...	1 411	202	7,0	3,0	1,8
10 A61K 45: Medicinal preparations containing active ingredients no...	1 372	163	8,4	3,6	1,9
11 A61P 33: Antiparasitic agents	1 262	88	14,3	5,5	2,1
12 A61P 1: Drugs for disorders of the alimentary tract or the digesti...	1 189	116	10,2	4,5	1,8
13 A61P 29: Non-central analgesic, antipyretic or antiinflammatory a...	1 133	105	10,8	4,5	2,0
14 A61Pmiss: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COM...	1 057	86	12,3	4,7	2,2
15 A61P 11: Drugs for disorders of the respiratory system	995	147	6,8	3,0	1,8
16 A61P 7: Drugs for disorders of the blood or the extracellular fluid	872	53	16,5	6,6	2,0
17 A61P 25: Drugs for disorders of the nervous system	851	91	9,4	4,4	1,9
18 A61K 35: Medicinal preparations containing materials or reaction ...	842	142	5,9	2,7	1,9
19 A61K 48: Medicinal preparations containing genetic material whic...	826	128	6,5	3,0	1,9
20 A61K 9: Medicinal preparations characterised by special physical...	766	150	5,1	2,2	1,9
21 A61P 3: Drugs for disorders of the metabolism (of the blood or t...	689	79	8,7	4,2	1,9
22 A61P 19: Drugs for skeletal disorders	657	70	9,4	4,3	2,0
23 A61K 51: Preparations containing radioactive substances for use ...	646	10	64,6	21,1	2,3
24 A61P 17: Drugs for dermatological disorders	577	56	10,3	4,7	2,0
25 A61P 9: Drugs for disorders of the cardiovascular system	488	60	8,1	4,1	1,9
26 A61P 13: Drugs for disorders of the urinary system (diuretics)	479	40	12,0	5,5	1,9
27 A61P 27: Drugs for disorders of the senses	444	47	9,4	4,2	1,9
28 A61P 21: Drugs for disorders of the muscular or neuromuscular s...	395	42	9,4	4,6	2,0

Европейская комиссия использует подход PatentSight в целях антимонопольного регулирования




Sources: LexisNexis PatentSight Analytics Platform; own research






Коронавирус: обзор международных СМИ

Общая динамика публикаций о коронавирусе



Распределение публикаций о коронавирусе по странам



Темы, упоминаемые в контексте обсуждения коронавируса

Respiratory Disease Sports & Recreation US Presidential Candidate...
Influenza Sports & Recreation Event...
Public Health Administrat... Infectious Disease
Legislative Bodies Coronaviruses Public Health Prices
Epidemics Viruses Death & Dying
Epidemiology Disease Agents & Vectors
Health Departments Diseases & Disorders
Disease Reporting Sars Wuhan Coronavirus
Communicable Disease Cont... Health Care Professionals
Students & Student Life Delays & Postponements

Компании, упоминаемые в контексте обсуждения коронавируса

Stagecoach Group JPMorgan Chase Air Canada
Walmart New York Stock Exchange Facebook, Inc.
Delta Air Lines PA Graphics The Canadian Press Oise
Southwest Airlines Agencia EFE, S.A. Starbucks easyJet
Sony Netflix Nasdaq, Inc. Apple Inc. Citigroup
Saudi Aramco Twitter BBC OPEC WhatsApp
Macron Bloomberg L.P. Amazon Agence France-Presse
Costco Uber Facebook Google Ryanair Spotify
Instagram Twitter, Inc. British Airways Microsoft Lufthansa
Boeing Control Data Corporation European Central Bank
Dow Jones & Company United Airlines The Walt Disney Company
Centers for Medicare and ... American Broadcasting Com... Formula One Group
American Airlines Postmedia Network

Персоны, упоминаемые в контексте обсуждения коронавируса

Olivier Veran Elizabeth Warren Muriel Bowser Jens Spahn Mark Esper
Scott Morrison Rodrigo Duterte Jerome Adams Bonnie Henry
Tedros Adhanom Ghebreyesu... Anthony Fauci Paul Gosar Mike Ryan
Ron DeSantis Bernie Sanders Gavin Newsom Angela Merkel
Nancy Pelosi Giuseppe Conte Joe Biden Ted Cruz Lucia Azzolina
Shinzō Abe **Donald Trump** Alex Azar Bill de Blasio
Justin Trudeau Mike Pence Rishi Sunak Shane Bond
Mike DeWine Andrew Cuomo Boris Johnson Narendra Modi
Barbara Ferrer Xi Jinping Jay Inslee Chris Whitty James Bond
Matt Gaetz Nadine Dorries Matt Hancock Emmanuel Macron
Evangelos Marinakis Matteo Bruni Benjamin Netanyahu
Larry Kudlow Steven Mnuchin Barack Obama Fernando Simón



Благодарю за Внимание!

Андрей Блинов

Bandr@chemrar.ru

+79853326753